Sponsored Content
Bridging Clinical and Commercial Drug Product Manufacturing – Outsourcing Advice from a CDMO
Learn how to mitigate manufacturing capacity issues and ensure your drug product is given the priority it deserves.
The point in drug development where a project moves from the clinical to the commercial stage often brings unforeseen challenges that may cause delays in bringing products to market. In this blog post, James S. Drob, Director of Manufacturing Operations, and Judy Cohen, VP of Quality Assurance at the CDMO Division of LLS Health, discuss how drug developers can mitigate capacity issues.
Click here to read the full blog Bridging Clinical and Commercial Drug Product Manufacturing – Outsourcing Advice from a CDMO from Lubrizol Life Science.
Drug shortages, especially for sterile injectables, have been a pressing issue for several years. While pharmaceutical CDMOs have invested in additional manufacturing capacity, market estimates still predict that demand for aseptic manufacturing services will outpace supply in the next two years.
Drug developers report difficulty finding CDMOs with both clinical and commercial manufacturing expertise to help them get to market. In addition, events of the last 12 months have seen COVID-19 vaccines and treatments prioritized by larger pharma companies and their manufacturing partners. This has further reduced available production capacity to commercialize new therapies.
Click here to learn more about our available aseptic manufacturing capacity and schedule a call with an expert from Lubrizol Life Science.
More Sponsored Content by Lubrizol Life Science Health
More Content From Lubrizol Life Science Health
-
In this white paper, Lubrizol Life Science Health reviews sterile pharmaceutical products, aseptic processing, methods of product sterilization and more.
-
This whitepaper explains how to navigate complex drug product formulation and freeze-drying cycle development to obtain a successful lyophilized drug product.
-
This whitepaper explores the development and manufacturing considerations associated with ophthalmic drug delivery, with a focus on retinal disorders.
-
HME is an efficient and trusted tool that improves solubility and enables the development of oral solid dosage forms from BCS Class II and IV compounds.
-
Several polymers are available for drug-device combination product developers, many that meet necessary regulatory requirements.